Patients in both cohorts were treated primarily with PD-1/PD-L1 therapies (microscopic colitis: 11/13, 84.6%; non-microscopic colitis: 16/25, 64.0%) (Table 1). The gene discussed is CD274; the disease is microscopic colitis.